These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8527710)

  • 61. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interferon versus interferon and UDCA combined therapy in chronic hepatitis C.
    Mazur W; Machniak M; Mazurek U; Jurzak M; Wilczok T; Gonciarz Z
    Med Sci Monit; 2001 May; 7 Suppl 1():157-64. PubMed ID: 12211712
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Significance of alanine aminotransferase screening in blood donors for risk reduction of hepatitis B and C transmission by haemotherapy].
    Kusendová K; Gavorník P; Sabaka P; Sviteková K
    Vnitr Lek; 2016 Jan; 62(1):9-16. PubMed ID: 26967232
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C.
    Takano S; Ito Y; Yokosuka O; Ohto M; Uchiumi K; Hirota K; Omata M
    Hepatology; 1994 Sep; 20(3):558-64. PubMed ID: 7521313
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.
    Di Bisceglie AM; Conjeevaram HS; Fried MW; Sallie R; Park Y; Yurdaydin C; Swain M; Kleiner DE; Mahaney K; Hoofnagle JH
    Ann Intern Med; 1995 Dec; 123(12):897-903. PubMed ID: 7486483
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Kato N; Yokosuka O; Imazeki F; Hashimoto E; Hayashi N; Nakamura A; Asada M; Kuroda H; Tanaka N; Arakawa Y; Omata M
    Gastroenterology; 1997 Aug; 113(2):558-66. PubMed ID: 9247476
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.
    Okazaki T; Yoshihara H; Suzuki K; Yamada Y; Tsujimura T; Kawano K; Yamada Y; Abe H
    Scand J Gastroenterol; 1994 Nov; 29(11):1039-43. PubMed ID: 7871371
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clearance of hepatitis C viral RNA in cirrhotic patients with antiviral therapy.
    Ono SK; da Silva LC; Carrilho FJ; da Fonseca LE; Mendes LC; Madruga CL; Farias Ade Q; Laudanna AA
    Rev Hosp Clin Fac Med Sao Paulo; 1996; 51(5):180-3. PubMed ID: 9216095
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.
    Rolandi E; Franceschini R; Cataldi A; Cicchetti V; Carati L; Barreca T
    Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
    Bini EJ; Mehandru S
    Aliment Pharmacol Ther; 2006 Mar; 23(6):777-85. PubMed ID: 16556180
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
    Parikh P; Ingle M; Patel J; Bhate P; Pandey V; Sawant P
    Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interferon alpha therapy in patients with chronic type C hepatitis: changes of serum ALT, anti-HCV & HCV-RNA.
    Cho HJ; Dong SH; Lee MS; Kim HY; Park CK; Yoo JY; Polito A; Quan S; Han JH
    Korean J Intern Med; 1992 Jan; 7(1):13-7. PubMed ID: 1282364
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.
    Reichard O; Yun ZB; Sönnerborg A; Weiland O
    J Med Virol; 1993 Oct; 41(2):99-102. PubMed ID: 8283183
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term ursodeoxycholate improves circulating redox changes in primary biliary cirrhotic patients.
    Grattagliano I; Palmieri VO; Portincasa P; Minerva F; Palasciano G
    Clin Biochem; 2011 Dec; 44(17-18):1400-4. PubMed ID: 21963381
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants.
    Al-Hathlol K; Al-Madani A; Al-Saif S; Abulaimoun B; Al-Tawil K; El-Demerdash A
    Singapore Med J; 2006 Feb; 47(2):147-51. PubMed ID: 16435058
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid.
    Tamai H; Okamura J
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851703
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA.
    Gracielle P; Roberta S; Ornella B; Luciana D; Alessandro R; Daniela Q; Gianpaolo L; Grazia D; Lamberto B; Anna C; Maurizio F; Alberto L
    Hepatol Res; 2002 Aug; 23(4):227. PubMed ID: 12191671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.